PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
PROTAGONIST THERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $166,632,000.00Stock-based compensation → Operating adjustments reconciliation: $28,556,000.00Prepaid expenses and other assets → Operating adjustments reconciliation: $2,299,000.00Non-cash lease expense → Operating adjustments reconciliation: $883,000.00Depreciation → Operating adjustments reconciliation: $804,000.00Deferred revenue → Operating adjustments reconciliation: $109,000.00Operating adjustments reconciliation → Net cash from operating activities: $3,477,000.00Operating adjustments reconciliation → Receivable from collaboration partner: $13,295,000.00Operating adjustments reconciliation → Accrued expenses and other payables: $6,602,000.00Operating adjustments reconciliation → Contract asset: $3,366,000.00Operating adjustments reconciliation → Accretion of discount on marketable securities: $2,071,000.00Operating adjustments reconciliation → Accounts payable: $1,897,000.00Operating adjustments reconciliation → Operating lease liability: $1,107,000.00Operating adjustments reconciliation → Other non-current assets: $832,000.00Operating adjustments reconciliation → Other: $4,000.00Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan → financing reconciliation: $33,117,000.00financing reconciliation → Net cash from financing activities: $33,117,000.00Proceeds from maturities of marketable securities → investing reconciliation: $289,105,000.00Proceeds from sale of marketable securities → investing reconciliation: $3,384,000.00investing reconciliation → Net cash from investing activities: $88,462,000.00investing reconciliation → Purchase of marketable securities: $203,644,000.00investing reconciliation → Purchases of property and equipment: $383,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $128,677,000.00Net cash from operating activities → Cash sources and uses: $170,109,000.00Net cash from financing activities → Cash sources and uses: $33,117,000.00Net cash from investing activities → Cash sources and uses: $88,462,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $420,365,000.00Net income (loss): $166,632,000.00Net income (loss)+$166.63 MNon-cash lease expense: $883,000.00Non-cash lease expense+$883.00 KOther: -$4,000.00Other operating, net−$4.00 KAccounts payable: -$1,897,000.00Trade payables−$1.90 MOperating lease liability: -$1,107,000.00Operating lease liabilities−$1.11 MDepreciation: $804,000.00Depreciation & amortization+$804.00 KAccretion of discount on marketable securities: -$2,071,000.00Investment discount & premium−$2.07 MStock-based compensation: $28,556,000.00Stock-based compensation+$28.56 MReceivable from collaboration partner: -$13,295,000.00Collaboration partner receivable−$13.30 MContract asset: -$3,366,000.00Contract assets−$3.37 MPrepaid expenses and other assets: $2,299,000.00Prepaid & other assets+$2.30 MOther non-current assets: -$832,000.00Other noncurrent assets−$832.00 KAccrued expenses and other payables: -$6,602,000.00Other payables & accruals−$6.60 MDeferred revenue: $109,000.00Deferred revenue+$109.00 KNet cash from operating activities: $170,109,000.00Operating cash+$170.11 MOperating adjustments reconciliation: $32,651,000.00Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan: $33,117,000.00Employee stock plans & options+$33.12 MNet cash from financing activities: $33,117,000.00Financing cash+$33.12 Mfinancing reconciliation: $33,117,000.00Purchase of marketable securities: -$203,644,000.00AFS securities purchases−$203.64 MProceeds from sale of marketable securities: $3,384,000.00Marketable securities proceeds+$3.38 MPurchases of property and equipment: -$383,000.00PP&E purchases−$383.00 KProceeds from maturities of marketable securities: $289,105,000.00AFS securities proceeds+$289.11 MNet cash from investing activities: $88,462,000.00Investing cash+$88.46 Minvesting reconciliation: $292,489,000.00Cash sources and uses: $420,365,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $128,677,000.00Beginning cash$128.68 MEnding cash: Cash, cash equivalents, and restricted cash: $420,365,000.00Ending cash$420.37 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$169.73 MOperating cash − cash spent on PP&ECash flow / Net income1.02×Operating cash flow ÷ net incomeNet cash change+$291.69 MEnding cash − beginning cash
Chart details

PROTAGONIST THERAPEUTICS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
128,677,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
170,109,000 US dollars. Net cash provided.
Net income (loss)
166,632,000 US dollars
Non-cash lease expense
883,000 US dollars
Other
negative 4,000 US dollars
Accounts payable
negative 1,897,000 US dollars
Operating lease liability
negative 1,107,000 US dollars
Depreciation
804,000 US dollars
Accretion of discount on marketable securities
negative 2,071,000 US dollars
Stock-based compensation
28,556,000 US dollars
Receivable from collaboration partner
negative 13,295,000 US dollars
Contract asset
negative 3,366,000 US dollars
Prepaid expenses and other assets
2,299,000 US dollars
Other non-current assets
negative 832,000 US dollars
Accrued expenses and other payables
negative 6,602,000 US dollars
Deferred revenue
109,000 US dollars
Investing activities
88,462,000 US dollars. Net cash provided.
Purchase of marketable securities
negative 203,644,000 US dollars
Proceeds from sale of marketable securities
3,384,000 US dollars
Purchases of property and equipment
negative 383,000 US dollars
Proceeds from maturities of marketable securities
289,105,000 US dollars
Financing activities
33,117,000 US dollars. Net cash provided.
Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan
33,117,000 US dollars
Operating adjustment reconciliation
32,651,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
33,117,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
292,489,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
420,365,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
420,365,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
291,688,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
1.02×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
170,109,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
383,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
169,726,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $3.48M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 170,109,000 US dollars minus 383,000 US dollars equals 169,726,000 US dollars.
PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!